FK506 in combination with methotrexate for the prevention of graft- versus-host disease after marrow transplantation from matched unrelated donors

Blood

Volumn 88, Issue 9, 1996, Pages 3634-3641

  Nash, Richard A ^a   Pin̈eiro, Luis A ^b   Storb, Rainer ^b   Deeg, H Joachim ^b   Fitzsimmons, William E ^b   Furlong, Terry ^b   Hansen, John A ^b   Gooley, Ted ^b   Maher, Rochelle M ^b   Martin, Paul ^b   McSweeney, Peter A ^b   Sullivan, Keith M ^b   Anasetti, Claudio ^b   Fay, Joseph W ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE; TACROLIMUS; THIOTEPA;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL CRISIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; DRUG MIXTURE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEADACHE; HLA MATCHING; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREMOR;

EID: 10344238083     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.9.3634.bloodjournal8893634     Document Type: Article

References (70)

1. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone-marrow transplantation (first of two parts). N Engl J Med 292:832, 1975
2. Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation, Boston, MA, Blackwell Scientific, 1994
3. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994
4. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W, Bryant E, Clift R, Deeg HJ, Doney K, Flowers M, Hansen J, Martin P, Pepe M, Sale G, Sanders J, Singer J, Sullivan KM, Thomas ED, Witherspoon RP: Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 84:941, 1994
5. Hansen JA, Clift RA, Thomas ED, Buckner CD, Storb R, Giblett ER: Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 303:565, 1980
6. Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL, Lawton C, Murray K, Hunter J, Baxter-Lowe LA, Gottschall JL, Oldham K, Anderson T, Camitta B, Menitove J: Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 322:485, 1990
7. Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ, Bearman SI, Anasetti C, Petersdorf EW, Mickelson EM, Pepe MS, Appelbaum FR, Buckner CD, Clift RA, Petersen FB, Stewart PS, Storb RF, Sullivan KM, Tesler MC, Witherspoon RP: Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 51:443, 1991
8. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stroncek D, Thomas ED, Blume KG: Analysis of 462 transplantations from unrelated donors facilitated by The National Marrow Donor Program. N Engl J Med 328:593, 1993
9. Hansen JA, Gooley T, Clift R, Petersdorf EW, Martin PJ, Anasetti C. Unrelated donor marrow transplants for patients with chronic myeloid leukemia. Blood 86:123a, 1995 (abstr, suppl 1)
10. Sullivan KM, Agura E, Anasetti C, Appelbaum FR, Badger C, Bearman S, Erickson K, Flowers M, Hansen JA, Loughran T, Martin P, Matthews D, Petersdorf E, Radich J, Riddell S, Rovira D, Sanders J, Schuening F, Siadak M, Storb R, Witherspoon RP: Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250, 1991.
11. Anasetti C, Hansen JA: Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus Sci 15:221, 1994
12. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
13. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, Hill R, Longton G, Lum L, Martin P, McGuffin R, Sanders J, Singer J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68:119, 1986
14. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilincyclosporine A and FKBP-FK506 complexes. Cell 66:807, 1991
15. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A: FK 506 for liver, kidney, and pancreas transplantation. Lancet 2:1000, 1989
16. U.S. Multicenter FK506 Liver Study Group: A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331:1110, 1994
17. European FK506 Multicentre Study Group: Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 344:423, 1994
18. Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE: Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation 52:590, 1991
19. Storb R, Raff RF, Appelbaum FR, Deeg HJ, Fitzsimmons W, Graham TC, Pepe M, Pettinger M, Sale G, Van Der Jagt R, Schuening FG: FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated DLA-nonidentical donors. Transplantation 56:800, 1993
20. Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, Appelbaum FR, Doney K, Martin P, Slattery J, Sullivan K, Van Der Jagt R, Witherspoon R, Jusko WJ, Zager RA, Deeg HJ: Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study. Blood 85:3746, 1995
21. Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, Aro RM, Weisdorf DJ: FK506 monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 87:3514, 1996
22. Brown RA, Wolff SN, Fay JW, Pineiro L, Collins RH Jr, Lynch JP, Stevens D, Greer J, Herzig RH, Herzig GP: High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: A study by the North American Marrow Transplant Group. Blood 85:1391, 1995
23. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382, 1987
24. Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey TR, Clift RA, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb R: Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. Blood 87:51, 1996
25. Dupont B, Yang SY: Histocompatibility, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation, Boston, MA, Blackwell Scientific, 1994, p 22
26. Hansen JA, Mickelson EM, Choo SY, Petersdorf EW, Anasetti C, Martin PJ, Thomas ED: Clinical bone marrow transplantation: Donor selection and recipient monitoring, in Rose NR, De Macario EC, Fahey JL, Friedman H, Penn GM (eds): Manual of Clinical Laboratory Immunology, Washington, DC, American Society for Microbiology, 1992, p 850
27. Petersdorf EW, Smith AG, Mickelson EM, Martin PJ, Hansen JA: Ten HLA-DR4 alleles defined by sequence polymorphisms within the DRB1 first domain. Immunogenetics 33:267, 1991
28. Tamura K, Kobayashi M, Hashimoto K, Kojima K, Nagase K, Iwasaki K, Kaizu T, Tanaka H, Niwa M: A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc 19:23, 1987
29. Jusko WJ, D'Ambrosio R: Monitoring FK506 concentrations in plasma and whole blood. Transplant Proc 23:2732, 1991
30. Grenier FC, Luczkiw J, Bergmann M, Lunetta S, Morrison M, Blonski D, Shoemaker K, Kobayashi M: A whole blood FK506 assay for the IMX analyzer. Transplant Proc 23:2748, 1991
31. Anasetti C, Anderson G, Appelbaum FR, Buckner CD, Martin PJ, Nemunaitis J, Singer J, Storb R, Sullivan KM, Thomas ED. Hansen JA: Phase III study of rhGM-CSF in allogeneic marrow transplantation from unrelated donors. Blood 82:454a, 1993 (abstr, suppl 1)
32. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multi-organ failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118:255, 1993
33. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone-marrow transplantation (second of two parts). N Engl J Med 282:895, 1975
34. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K, Thomas ED: Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 57:267, 1981
35. Spencer GD, Hackman RC, McDonald GB, Amos DE, Cunningham BA, Meyers JD, Thomas ED: A prospective study of unexplained nausea and vomiting after marrow transplantation. Transplantation 42:602, 1986
36. Weisdorf DJ, Snover DC, Haake R, Miller WJ, McGlave PB, Blazar B, Ramsay NKC, Kersey JH, Filipovich A: Acute upper gastrointestinal graft-versus-host disease: Clinical significance and response to immunosuppressive therapy. Blood 76:624, 1990
37. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, Beatty PG, Doney K. McDonald GB, Sanders JE, Sullivan KM, Storb R, Thomas ED, Witherspoon RP, Lomen P, Hannigan J. Hansen JA: A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 76:1464, 1990
38. Martin PJ, Nelson BJ, Appelbaum FR, Anasetti C, Deeg HJ, Hansen JA, McDonald GB, Nash RA, Sullivan KM, Witherspoon RP, Scannon PJ, Friedmann N, Storb R: Evaluation of aCD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 88:824, 1996
39. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlbcrg S, Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C, Loughran TP, Hill R, Shields A, Yee G, Shulman H, Nims J, Strom S, Thomas ED: Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood 72:555, 1988
40. Loughran TP Jr, Sullivan K. Morton T, Beckham C, Schubert M, Witherspoon R, Sale G, Sanders J, Fisher L. Shulman H, Thomas ED, Storb R: Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Blood 76:228, 1990
41. Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R: Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: Motivation for and description of new methods. Br J Haematol 83:602, 1993
42. Pepe MS, Mori M: Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12:737, 1993
43. Nielsen FT, Leyssac PP, Kemp E, Starklint H, Dieperink H: Nephrotoxicity of FK-506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity. Nephrology, Dialysis. Transplantation 10:334, 1995
44. Moutabarrik A, Ishibashi M, Fukunaga M, Kameoka H, Kawaguchi N, Takano Y, Kokado Y, Sonoda T, Onishi S, Takahara S, Okuyama A: FK506-induced kidney tubular cell injury. Transplantation 54:1041, 1992
45. Kumano K, Wang G, Endo T: FK506-induced nephrotoxicity in rats. Transplant Proc 23:512, 1991
46. Demetris AJ, Banner B, Fung J, Shapiro R, Jordan M, Starzl TE: Histopathology of human renal allograft rejection under FK506: A comparison with cyclosporine. Transplant Proc 23:944, 1991
47. Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Bennett WM: Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation 57:483, 1994
48. Zager RA, O'Quigley J, Zager BK, Alpers CE, Shulman HM, Gamelin LM, Stewart P, Thomas ED: Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kidney Dis 13:210, 1989
49. Eliashiv S, Brenner T, Abramsky O, Shahin R, Agai E, Naparstek E, Steiner I: Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation. Bone Marrow Transplant 8:315, 1991
50. Perry A, Mehta J, Iveson T, Treleaven J, Powles R: GuillainBarre syndrome after bone marrow transplantation. Bone Marrow Transplant 14:165, 1994
51. Hagensee ME, Benyunes M, Miller JA, Spach DH: Campylobacter jejuni bacteremia and Guillain-Barre syndrome in a patient with GVHD after allogeneic BMT. Bone Marrow Transplant 13:349, 1991
52. Myers SE, Williams SF: Guillain-Barre syndrome after autologous bone marrow transplantation for breast cancer: Report of two cases. Bone Marrow Transplant 13:341, 1994
53. Carozzi M, De Manzini A, Giorgi A, Osbish A: Acute inflammatory polyradiculoneuritis during bone marrow transplantation. A report of 2 cases. Pediatr Med Chir 16:163, 1994
54. Mudad R, Hussein A, Peters WP: Guillain-Barre syndrome following autologous bone marrow transplantation. Am J Clin Oncol 18:167, 1995
55. Wilson JR, Conwit RA, Eidelman BH, Starzl T, Abu-Elmagd K: Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve 17:528, 1994
56. Rabinowe SN, Soiffet RJ, Tarbell NJ, Neuberg D, Freedman AS. Seifter J, Blake KW, Gribben JG, Anderson KC, Takvorian T, Ritz J, Nadler LM: Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 77:1837, 1991
57. Holler E, Kolb HJ, Hiller E, Mraz W, Lehmacher W, Gleixner B, Seeber C, Jehn U, Gerhartz HH, Brehm G, Wilmanns W: Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 73:2018, 1989
58. Van Buren D, Van Buren CT, Flechner SM, Maddox AM, Verani R, Kahan BD: De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 98:54, 1985
59. Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, Banaji M, Appelbaum FR, Bensinger WI, Buckner CD, Clift RA, Doney K, Fefer A, McGuffin R, Sanders JE, Singer J, Stewart P, Sullivan KM, Witherspoon RP: Cyclosporine as prophylaxis for graft-versus-host disease: A randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 65:1325, 1985
60. Yee GC, Kennedy MS, Deeg HJ, Leonard TM, Thomas ED, Storb R: Cyclosporine-associated renal dysfunction in marrow transplant recipients. Transplant Proc 17:196, 1985
61. Tzakis AG, Abu-Elmagd K, Fung JJ, Bloom EJ, Nour B, Greif F, Starzi TE: FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc 23:3225, 1991
62. Reding R, Wallemacq PE, Lamy ME, Rahier J, Sempoux C, Debande B, Jamart J, Barker A, Sokal E, de Ville de Goyet J, Moulin D, de Clety SC, Otte J-B: Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Transplantation 57:93, 1994
63. Jordan ML, Shapiro R, Vivas CA, Scantlebury VP, Rhandhawa P, Carrieri G, McCauley J, Demetris AJ, Tzakis A, Fung JJ, Simmons RL, Hakala TR, Starzl TE: FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 57:860, 1994
64. Egawa H, Esquivel CO, So SK, Cox K, Concepcion W, Lawrence L: FK506 conversion therapy in pediatric liver transplantation. Transplantation 57:1169, 1994
65. Swenson JM, Fricker FJ, Armitage JM: Immunosuppression switch in pediatric heart transplant recipients: Cyclosporine to FK506. J Am Coll Cardiol 25:1183, 1995
66. Keenan RJ, Konishi H, Kawai A, Paradis IL, Nunley DR, Iacono AT, Hardesty RL, Weyant RJ, Griffith BP: Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 60:580, 1995
67. Starzl TE, Donner A, Eliasziw M, Stitt L, Meier P, Fung JJ, McMichael JP, Todo S: Randomized trialomania? The multicentre liver transplant trials of tacrolimus. Lancet 346:1346, 1995
68. Morris RE, Brown BW Jr: Tacrolimus for prevention of liver allograft rejection: clinical trials and tribulations. Lancet 346:1310, 1995
69. Pai SY, Fruman DA, Leong T, Neuberg D, Rosano TG, McGarigle C, Antin JH, Bierer BE: Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood 84:3974, 1994
70. Sierra J, Storer B, Hansen J, Martin P, Petersdorf E, Appelbaum F, Buckner D, Sale G, Sanders J, Anasetti C: Unrelated donor marrow transplants (URD-BMT) for acute leukemia (AL). Blood 86:290a, 1995 (abstr, suppl 1)